Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox(George Washington University), Alejandro Villagra(Georgetown University)
Cited by 160
Related Papers
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
|International Journal of Molecular Sciences|2019|149